Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Cisplatin
32%
Prevalence
32%
Bone Metastasis
32%
Gemcitabine
32%
Muscle Invasive Bladder Cancer
32%
Vinflunine
32%
Fluorine 18
32%
Disease
32%
Sodium Fluoride
32%
Prostate Specific Membrane Antigen
32%
Lutetium 177
32%
Symptom
32%
Tasquinimod
32%
Castration Resistant Prostate Cancer
32%
Clinical Trial
21%
Adverse Event
18%
Malignant Neoplasm
18%
Long Term Survival
16%
Cross-Sectional Study
16%
Nocturia
16%
Chemotherapy
10%
Diarrhea
10%
Adenocarcinoma
10%
Medicine and Dentistry
Prostate Cancer
97%
Patient-Reported Outcome
40%
Progressive Disease
32%
Bone Scintigraphy
32%
Pelvis
32%
Treatment Response
32%
Bone Metastasis
32%
Testis Cancer
32%
Fluorine-18
32%
Clinical Stage
32%
Positron Emission Tomography-Computed Tomography
32%
Patient Characteristics
24%
Urinary System
21%
Quality of Life
18%
Prevalence
16%
Proportional Hazards Model
16%
Clinical Trial
10%
Intensity Modulated Radiation Therapy
10%
Rank Sum Test
8%
Cancer Epidemiology
8%
Disease Specific Survival
8%
Outcome Assessment
8%
Log Rank Test
8%
Adjuvant Therapy
8%
Chorionic Gonadotropin
8%
Orchiectomy
8%
Overall Survival
8%
Hormone Therapy
6%
Intestine Function
5%
Diarrhea
5%
Adenocarcinoma
5%
Mucus
5%
Lymph Node
5%
Keyphrases
VISION Study
35%
Safety Analysis
32%
Advanced Urothelial Carcinoma
32%
Cisplatin-ineligible
32%
Prostate-specific Antigen
32%
Vinflunine
32%
Docetaxel Chemotherapy
32%
Urinary Morbidity
32%
Pelvic Radiation
32%
Tasquinimod
32%
Lutetium-177 (177Lu)
32%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
32%
Treatment-related Adverse Events
18%
Standard of Care
16%
Seminoma
13%
Clinical Stage I
13%
Nonseminoma
9%
Radiographic Progression-free Survival
8%
6-cycle
6%
3-week Schedule
5%
Physician-reported Outcome
5%
Sexual Morbidity
5%
